Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself | ||
By: Nasdaq / GlobeNewswire - 31 Jan 2018 | Back to overview list |
|
FIT Biotech Oy FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself FIT Biotech Oy's Board of Directors has resolved to issue 100,000,000 new K shares without payment to the Company itself based on the authorization granted by the extraordinary general meeting on December 14, 2017 (Extraordinary general meeting Point 9§). The total authorization was 550,000,000 K shares. The Board of Directors has decided earlier on December 27, 2017 to issue 80,000,000 new K shares. There are authorizations for 370,000,000 K shares left after this issuance. The purpose is partly to use the shares to implement the new Alpha Blue Ocean funding programme, disclosed on December 23, 2017 and partly to implement the remaining part of the Bracknor funding programme. FIT BIOTECH OY For further information: Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000 About FIT Biotech FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines. FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy. DISTRIBUTION: |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |